Activating the Potential of Gamma Delta T-Cells in Preclinical Models: A Next-Generation Strategy to Minimise CRS & Rethink TCE Safety in Autoimmunity
- Introduction to the potential of gamma delta T-cells and tackling the challenge of their limited presence in patients by engineering engagers that expand and activate these cells in vivo without relying on CD3 stimulation
- Exploring ways to safely increase levels of rare immune cells like gamma delta T-cells and NK cells inside the body for effective targeting
- Discuss limitations of oncology-based animal models for autoimmune settings and examine strategies with gamma delta T-cells to validate lymphoid tissue targeting, depletion efficacy, and safety in the absence of conventional cytokine-driven biomarkers